CD47 Targeting Therapeutics on Target A Multi-Billion Dollar Market Revolutionizing Cancer Immunotherapy

CD47 Targeting Therapeutics Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic

Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type of Molecule (Biologics and Small Molecule), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get a free sample copy of the report : https://www.insightaceanalytic.com/request-sample/1290

As per the most recent study conducted by Insight Analytics, the global market for CD47 targeting therapeutics is anticipated to have a compound annual growth rate (CAGR) of 67% from 2024 to 2031. Many cancer cells have glycosylated surfaces, which help cancer cells survive in different types of cancer. This transmembrane protein is termed CD47. In many kinds of cancer, CD47 blocks malignant cells from being phagocytosed by macrophages by its binding to the signal-regulatory protein SIRP, initiating an inhibitory signalling cascade. Thus, it is possible to encourage macrophage phagocytosis of cancer cells by inhibiting the CD47-SIRP signalling pathway.

The growing use of CD47-targeted anti-cancer medications, an ageing population, a high incidence of different cancer kinds, and growing public knowledge of these treatments' benefits are some factors driving the growth of the global market for CD47-targeting therapeutics. It is also anticipated that increasing R&D expenditure to understand better CD47-dependent signalling would create new opportunities for the market for CD47-targeted therapies throughout the projection period. Developing novel anti-tumour therapies that block CD47 signalling in cancer cells could be possible with a deeper comprehension of this field of study.

The market acceptance is expected to be limited throughout the projected years, though, because of the high cost of production and complicated manufacturing of target therapies, their potential to harm normal cells while having an anti-tumour effect, and stringent government regulations surrounding therapeutic approvals. The market for CD47 Targeting Therapeutics is expected to benefit from contributions from North America during the projected years. Because the number of cancer patients and deaths in the area is increasing and because new drugs and treatment techniques are being adopted quickly.

The US is vital in funding research and development for CD47-targeting medications. Furthermore, the Asia Pacific CD47 Targeting Therapeutics market is anticipated to develop substantially throughout the projected period. Some factors driving the growth of the CD47 targeting therapeutics market in this region include the increasing use of CD47-targeting anti-cancer therapies, an ageing population, the high prevalence of various cancer types, and growing public awareness of the advantages of targeting therapeutics.

Major market players operating in the CD47 Targeting Therapeutics market include

Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others.

Recent collaborations and agreements in the market:

• In January 2022, the next-generation CD47 blocker evorpacept, manufactured by ALX Oncology, was accorded orphan drug designation ("ODD") for treating patients with gastroesophageal junction and gastric cancer.

• In September 2021, for US$2.3 billion, Pfizer Inc. (US) purchased Trillium Therapeutics Inc. (Canada), which had CD47 prospects. Pfizer now has a stronger cancer and hematology portfolio thanks to this acquisition.

• In June 2021, to test the efficacy of combining ALX148, a next-generation CD47 blocker, and CYRAMZA (ramucirumab), Lilly's anti-VEGFR2 antibody, for the treatment of gastric cancer, ALX Oncology (US) and Eli Lilly and Company (US) agreed into a clinical study partnership and supply agreement.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1290

Market Segments
Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Value US$ Mn)

• Acute Myeloid Leukemia
• Non-Hodgkin Lymphoma
• Colorectal Cancer
• Diffuse Large B-cell Lymphoma
• Myelodysplastic Syndromes
• Non-Small Cell Lung Cancers
• Ovarian Epithelial Cancer
• Oral mucositis
• Small Cell Lung Cancers
• Other Diseases Indications

Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)

• Biologics
• Small Molecule

Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• U.S.
• Canada

Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• GCC Countries
• South Africa
o Rest of Middle East & Africa

Why should buy this report:

 To receive a comprehensive analysis of the prospects for the global CD47 Targeting Therapeutics market

 To receive an industry overview and future trends in the CD47 Targeting Therapeutics market

 To analyze the CD47 Targeting Therapeutics market drivers and challenges

 To get information on the CD47 Targeting Therapeutics market value (US$Mn) forecast to 2030

 Significant investments, mergers & acquisitions in the CD47 Targeting Therapeutics market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1290

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.